Phathom Pharmaceuticals, Inc. PHAT Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by Phathom Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: Phathom Pharmaceuticals, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Phathom Pharmaceuticals, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Phathom Pharmaceuticals, Inc.'s deferred revenue?
- Phathom Pharmaceuticals, Inc. (PHAT) reported deferred revenue of $33.02M in Q1 2026.
- How has Phathom Pharmaceuticals, Inc.'s deferred revenue changed year-over-year?
- Phathom Pharmaceuticals, Inc.'s deferred revenue increased by 91.2% year-over-year, from $17.27M to $33.02M.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.